Correction: Two roads for oncolytic immunotherapy development

• Michael Timaner,
• Ziv Raviv,
• Shai Shen-Orr,
• Yuval Shaked,
• Tongwu Zhang,
• Ksenia Magidey-Klein,
• Tim J Cooper,
• Ksenya Kveler,
• Rachelly Normand,
• Brian P. James,
• Roi Gazit,
• Ze'ev A. Ronai

Affiliations

Michael Timaner

Technion-integrated cancer center, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel

Ziv Raviv

Rappaport Faculty of Medicine, Rappaport Technion Integrated Cancer Center, Technion Israel Institute of Technology, Haifa, Israel

Shai Shen-Orr

Department of Immunology, Ruth and Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel

Yuval Shaked

Rappaport Faculty of Medicine, Rappaport Technion Integrated Cancer Center, Technion Israel Institute of Technology, Haifa, Israel

Tongwu Zhang

1 Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland, USA

Ksenia Magidey-Klein

Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel

Tim J Cooper

Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel

Ksenya Kveler

Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel

Rachelly Normand

Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel

Brian P. James

Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA

Roi Gazit

Department for Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, Southern, Israel

Ze'ev A. Ronai

Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA